An act relating to prohibiting pharmacy benefit managers from owning or operating a pharmacy in Vermont
H.156 is a short-form Vermont bill that would prohibit pharmacy benefit managers, or PBMs, from owning or operating a pharmacy in the state. The bill is framed as a health and pharmacy regulation measure and is aimed at separating PBM business activities from retail pharmacy ownership or operation. Because the text is introduced in short form, the specific statutory amendments are not shown in the bill text provided, but the stated purpose is clear: to bar PBM vertical integration into pharmacy operations in Vermont.
If enacted, the bill would likely affect state pharmacy licensing and business-ownership rules by creating a new restriction on who may own or run a pharmacy. It would directly impact PBMs, pharmacy chains or affiliated entities with PBM ownership, and potentially independent pharmacies and consumers through changes in market structure. The measure could also require enforcement by state regulators responsible for pharmacy licensure and compliance.
The bill would change Vermont law by adding a prohibition on pharmacy benefit managers owning or operating pharmacies in the state. That would likely require amendments to existing pharmacy licensing, ownership, and enforcement provisions, and could affect corporate structures that combine PBM and pharmacy functions. The practical effect would be to limit vertically integrated pharmacy/PBM business models and could alter competition, access, and reimbursement relationships in the pharmacy market.
Based on the limited available context, the bill appears to be introduced as a policy response to concerns about PBM influence in the pharmacy market, suggesting a reform-oriented or skeptical view of PBM ownership of pharmacies. There are no committee transcripts or recorded votes provided, so no formal support or opposition can be measured from the available record. The overall sentiment in the bill text is regulatory and restrictive rather than neutral or permissive.
The central point of contention is likely whether PBMs should be allowed to own or operate pharmacies at all. Supporters would likely argue that prohibiting PBM ownership reduces conflicts of interest, improves fairness in drug pricing and reimbursement, and protects independent pharmacies. Opponents would likely argue that the restriction could reduce competition, limit business flexibility, and potentially affect consumer access or efficiency. Because no hearing transcript or vote history is provided, the specific positions of legislators, industry groups, or pharmacy stakeholders are not documented in the available materials.